Results
Ernexa Therapeutics Inc.
02/05/2026 | Press release | Distributed by Public on 02/05/2026 10:34
New Listing Registration (Form 8-A12B)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
For Registration of Certain Classes of Securities
Pursuant to Section 12(b) or 12(g) of the
Securities Exchange Act of 1934
| ERNEXA THERAPEUTICS INC. |
| (Exact name of registrant as specified in its charter) |
| Delaware | 31-1103425 | |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
|
1035 Cambridge Street, Suite 18A Cambridge, MA |
02141 | |
| (Address of principal executive offices) | (Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
Title of each class to be so registered |
Name of each exchange on which each class is to be registered |
|
| Warrants, each warrant exercisable for one share of common stock, par value $0.005 per share | The Nasdaq Stock Market LLC |
If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒
If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this Form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333- 293150
Securities to be registered pursuant to Section 12(g) of the Act:
| None |
| (Title of class) |
INFORMATION REQUIRED IN REGISTRATION STATEMENT
| Item 1. | Description of the Registrant's Securities to be Registered. |
The securities to be registered hereby are Common Warrants of Ernexa Therapeutics Inc. (the "Company"). For a description of the Warrants, reference is made to the information under the heading "Description of the Securities to be Registered" included in the prospectus that constitutes a part of the Company's Registration Statement on Form S-1 (File No. 333-293150), dated February 5, 2026 (the "Registration Statement"), which information is incorporated herein by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.
| Item 2. | Exhibits. |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereto duly authorized.
| Date: | February 5, 2026 | ||
| ERNEXA THERAPEUTICS INC. | |||
| By: | /s/ Sanjeev Luther | ||
| Name: | Sanjeev Luther | ||
| Title: | Chief Executive Officer | ||
Ernexa Therapeutics Inc. published this content on February 05, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 05, 2026 at 16:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]